Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Britain trials embryonic stem cells as treatment for blindness

26 September 2011

By Dr Rachael Panizzo

Appeared in BioNews 626

UK scientists have been granted approval to begin the first clinical trial using embryonic stem cells (ES cells) in Europe, which they hope could lead to an effective treatment for a degenerative eye disease causing blindness. The team at Moorfield's Eye Hospital in London will inject stem cells into the eye's of patients with Stargardt's macular dystrophy, a genetic condition that causes blindness, in order to test the safety of the stem cell therapy.

The trial was approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the researchers will now start the process of recruiting 12 patients with advanced Stargardt's macular dystrophy to participate in the study. The patients will receive an injection of between 50,000 and 200,000 cells behind the retina.

The researchers hope the treatment will halt or even reverse the progression of the disease. 'It's more realistic that it will protect against further sight loss', said Professor James Bainbridge, a retinal surgeon at Moorfield's Eye Hospital who is leading the trial. He added that if the trial is a success, the treatment could become a routine procedure within five years.

'There is a real potential that people with blinding disorders of the retina, including Stargardt's disease and age-related macular degeneration, might benefit in the future from transplantation of retinal cells', Professor Bainbridge said.

Stargardt's macular dystrophy is a genetic condition that causes degeneration of the light sensitive photoreceptor cells in the eye's retina, and of the retinal pigment epithelial (RPE) cells that lie beneath and support the retina. The disease affects around 5,000 people in Britain, and is normally diagnosed in patients between 10 and 20 years of age.

The study will use human ES cells to generate healthy RPE cells in the laboratory for injecting into the eye. The technology was developed by the US biotechnology company Advanced Cell Technology (ACT), which is involved in the UK clinical trial and conducting a similar trial in the United States.

Chris Mason, Professor of Regenerative Medicine at University College London, said: 'ACT, a leading US company, by undertaking this important clinical trial in London, endorses the UK's position as world leaders in stem cell therapies. This is the first application of an embryonic stem cell-based therapy into the eye'.

The potential of ES cells to help regenerate damaged tissue has long been recognised, and has been a major goal of regenerative medicine since a method to grow these cells in the laboratory was established more than a decade ago. But the use of ES cells raises ethical questions because their creation involves the destruction of human embryos. The UK trial is one of the first to translate ES research into the clinical setting.

Professor Colin Blakemore from the University of Oxford said: 'The ultimate justification for all of the work that has been done is that it will lead to a great advance in medical treatment. It's good to see this progress towards such applications'.

But he added: 'It is very important that expectations are not unrealistically raised, and that people distinguish between legitimate trials such as this one and the many bogus and potentially dangerous treatments that you can find on the internet and abroad'.

SOURCES & REFERENCES
The Times | 23 September 2011
 
BBC | 22 September 2011
 
Independent | 23 September 2011
 
Financial Times | 22 September 2011
 
Guardian | 22 September 2011
 
Telegraph | 22 September 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

29 July 2013 - by Dr Greg Ball 
Light-sensitive cells found in the retina have been grown from mouse embryonic stem cells (ESCs) and successfully transplanted into the eyes of visually impaired mice, restoring some vision...
06 February 2012 - by Ruth Retassie 
US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...
31 January 2012 - by Rosemary Paxman 
A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA...
31 January 2012 - by Dr Dusko Ilic and Dr Emma Stephenson 
Last week, Advanced Cell Technology (ACT) of Massachusetts, USA, made two important announcements regarding human embryonic stem (hES) cell-based therapies for the potential treatment of Stargardt's dystrophy and age-related macular degeneration, two devastating degenerative disease leading to blindness....
12 December 2011 - by Julianna Photopoulos 
A new Technology and Innovation Centre in Cell Therapy will open in London and receive funding of up to £50 million, the Technology Strategy Board announced. The new cell therapy centre, due to open in April 2012, is part of a £220 million programme to boost technology and manufacturing in the UK...

18 July 2011 - by Dr Sophie Pryor 
Doctors in the USA have begun treating patients in two clinical trials for degenerative eye diseases. The studies at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA), will test whether specialised eye cells, which have been produced from human embryonic stem cells (hESCs), can be used to treat dry age-related macular degeneration (dry AMD) and Stargardt's macular dystrophy....
27 June 2011 - by Dr Nadeem Shaikh 
A group of US scientists has successfully used a virus to deliver genes into monkey retinas that could potentially restore damaged photoreceptor cells. The findings could lead to gene therapies being developed to treat blindness and other eye conditions in humans...
11 April 2011 - by Dr Rachael Panizzo 
Embryonic stem cells have been used to generate a basic retina, the part of the eye that detects light and is needed for vision. The retinal tissue could be used to treat some forms of blindness, such as retinitis pigmentosa and age-related macular degeneration, and to investigate and screen potential new drugs for a range of eye diseases....
28 March 2011 - by Dr Sophie Pryor 
US scientists have taken an important step towards using stem cells to treat age-related macular degeneration (AMD), the leading cause of blindness in the UK. The study demonstrates, for the first time, the ability to direct human iPS (induced pluripotent stem) cells to become...
21 March 2011 - by Dr Lux Fatimathas 
UK scientists have shown stem cells can be used to successfully stop glaucoma, an eye disorder, in rats. Stem cells were isolated from bone marrow and successfully grafted onto damaged nerves in the eye...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation